Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of the cohort overall and by ART delivery site

From: Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study

   Overall By ART delivery site
    Site A Site B Site C Site D Site E
  n 953 165 238 198 145 207
Age (years) Median 41 38 39 44 39 44
  IQR 35–46 34–41 34–44 39–48 32–46 37–49
Sex Male (%) 95.9 97.0 97.1 99.0 91.0 94.2
CD4 (× 106/l) Median 156 177 140 160 131 169
  (IQR) 86–230 106–280 77–205 83–250 88–185 101–222
WHO stage* 1–2 (%) 27.0 16.0 12.8 28.4 38.8 45.7
  3 46.2 36.4 47.7 53.6 45.5 45.7
  4 26.8 47.5 39.6 18.0 15.7 8.7
Viral load (copies/ml) <= 10,000 (%) 20.1 20.1 20.5 18.1 16.7 24.0
  10,001–100,000 49.7 46.5 50.5 51.3 48.6 50.5
  >100,000 30.3 33.3 29.0 30.6 34.8 25.5
Weight (kg) Median 63 64 65 61 60 65
  IQR 57–69 59–69 59–70 56–68 52–67 60–73
ART regimen COM/EFV (%) 94.1 96.4 94.5 97.0 86.9 94.2
  1. ART = antiretroviral therapy; IQR = interquartile range; WHO = World Health Organization; COM = Combivir; EFV = Efavirenz
  2. * clinical staging of HIV disease (see methods for definition).